These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
232 related items for PubMed ID: 12692781
1. Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1alpha,24-dihydroxyvitamin D2. Bauer JA, Thompson TA, Church DR, Ariazi EA, Wilding G. Prostate; 2003 May 15; 55(3):159-67. PubMed ID: 12692781 [Abstract] [Full Text] [Related]
2. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF. Clin Cancer Res; 2000 Mar 15; 6(3):901-8. PubMed ID: 10741714 [Abstract] [Full Text] [Related]
3. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Murthy S, Agoulnik IU, Weigel NL. Prostate; 2005 Sep 01; 64(4):362-72. PubMed ID: 15754350 [Abstract] [Full Text] [Related]
4. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G, Klocker H. Cancer Gene Ther; 2000 Jul 01; 7(7):997-1007. PubMed ID: 10917202 [Abstract] [Full Text] [Related]
5. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z. Clin Cancer Res; 2001 Sep 01; 7(9):2941-8. PubMed ID: 11555613 [Abstract] [Full Text] [Related]
6. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P. Cancer Res; 1992 Feb 01; 52(3):515-20. PubMed ID: 1370648 [Abstract] [Full Text] [Related]
7. Regulation of aromatase and 5alpha-reductase by 25-hydroxyvitamin D(3), 1alpha,25-dihydroxyvitamin D(3), dexamethasone and progesterone in prostate cancer cells. Lou YR, Murtola T, Tuohimaa P. J Steroid Biochem Mol Biol; 2005 Feb 01; 94(1-3):151-7. PubMed ID: 15862960 [Abstract] [Full Text] [Related]
8. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts. Chiu FL, Lin JK. Prostate; 2008 Jan 01; 68(1):61-71. PubMed ID: 18008333 [Abstract] [Full Text] [Related]
9. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Díaz GD, Paraskeva C, Thomas MG, Binderup L, Hague A. Cancer Res; 2000 Apr 15; 60(8):2304-12. PubMed ID: 10786699 [Abstract] [Full Text] [Related]
10. The novel analog 1,24(S)-dihydroxyvitamin D2 is as equipotent as 1,25-dihydroxyvitamin D3 in growth regulation of cancer cell lines. Levy Y, Knutson JC, Bishop C, Shany S. Anticancer Res; 1998 Apr 15; 18(3A):1769-75. PubMed ID: 9673403 [Abstract] [Full Text] [Related]
11. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP). Koochekpour S, Lee TJ, Wang R, Culig Z, Delorme N, Caffey S, Marrero L, Aguirre J. Prostate; 2007 Feb 01; 67(2):178-89. PubMed ID: 17044040 [Abstract] [Full Text] [Related]
13. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Gregory CW, Johnson RT, Mohler JL, French FS, Wilson EM. Cancer Res; 2001 Apr 01; 61(7):2892-8. PubMed ID: 11306464 [Abstract] [Full Text] [Related]
14. Androgen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells. Cronauer MV, Nessler-Menardi C, Klocker H, Maly K, Hobisch A, Bartsch G, Culig Z. Br J Cancer; 2000 Jan 01; 82(1):39-45. PubMed ID: 10638964 [Abstract] [Full Text] [Related]
15. Effect of calcitriol on prostate-specific antigen in vitro and in humans. Beer TM, Garzotto M, Park B, Mori M, Myrthue A, Janeba N, Sauer D, Eilers K. Clin Cancer Res; 2006 May 01; 12(9):2812-6. PubMed ID: 16675575 [Abstract] [Full Text] [Related]
16. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells. Serda RE, Bisoffi M, Thompson TA, Ji M, Omdahl JL, Sillerud LO. Prostate; 2008 May 15; 68(7):773-83. PubMed ID: 18247401 [Abstract] [Full Text] [Related]
17. Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase. Trofimova I, Dimtchev A, Jung M, Rosenthal D, Smulson M, Dritschilo A, Soldatenkov V. Cancer Res; 2002 Dec 01; 62(23):6879-83. PubMed ID: 12460902 [Abstract] [Full Text] [Related]
18. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Arnold JT, Le H, McFann KK, Blackman MR. Am J Physiol Endocrinol Metab; 2005 Mar 01; 288(3):E573-84. PubMed ID: 15536203 [Abstract] [Full Text] [Related]
19. 1alpha,25-Dihydroxyvitamin D3-3beta-(2)-bromoacetate, an affinity labeling derivative of 1alpha,25-dihydroxyvitamin D3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cells. Swamy N, Persons KS, Chen TC, Ray R. J Cell Biochem; 2003 Aug 01; 89(5):909-16. PubMed ID: 12874825 [Abstract] [Full Text] [Related]
20. Androgen and taxol cause cell type-specific alterations of centrosome and DNA organization in androgen-responsive LNCaP and androgen-independent DU145 prostate cancer cells. Schatten H, Ripple M, Balczon R, Weindruch R, Chakrabarti A, Taylor M, Hueser CN. J Cell Biochem; 2000 Jan 01; 76(3):463-77. PubMed ID: 10649443 [Abstract] [Full Text] [Related] Page: [Next] [New Search]